ReviewMedical oncology (Northwood, London, England)2026
Updates on niosomes in interfering nucleic acid delivery for cancer treatment: A comprehensive review and future perspectives.
Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer continues to be one of the top killers worldwide. Traditional treatment strategies like chemotherapy, radiation, and surgery have non-specific treatment options with considerable side effects. Gene-based therapies using nucleic acids like siRNA, miRNA, and DNAzymes provide an alternative approach; however, issues with stability, delivery, and off-target effects continue to plague their clinical use. Niosomes, or non-ionic surfactant vesicles, provide a flexible and inexpensive alternative to circumvent many of these issues. This review will present the niosomal systems for nucleic acid delivery in cancer therapy. Niosomes have key advantages compared to traditional delivery vehicles due to their chemical stability and biocompatibility, and ease of surface modifications. Their ability to carry a range of nucleic acids and allow for endosomal escape makes niosomes ideal candidates for targeted, multimodal therapies. Critical therapeutic applications include co-delivery of nucleic acids with chemotherapeutic drugs to improve synergistic activity, reprogramming the tumor microenvironment to increase immune response, and bypassing mechanisms of tumor resistance. In addition, the incorporation of external triggers, such as magnetic and ultrasound responsive elements, provides precise spatiotemporal control over nucleic acid release. The review outlines exciting research improvements of niosomal formulations based on surface charge, ligand targeting, and new genetic payloads, underscoring the state-of-the-art potential of niosomes for personalized cancer treatments. niosomes showed low immunogenicity and good pharmacokinetics in preclinical research, suggesting they are highly translational and leading-edge for next-generation cancer treatments.
Indexed as
Identifiers
41642377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.